Anti‐rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity
Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Riccardo Bruna(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Umberto Dianzani(University of Turin), Elena Crisà(Candiolo Cancer Institute), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Casimiro Luca Gigliotti, Gloria Margiotta Casaluci(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Elena Boggio(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Roberta Rolla(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 9
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378